We measured the expression of MHC class I and PD-L1 in cancer cell lines testing two different doses of DAC; 1 μM DAC is considered a clinically relevant dose in acute myeloid leukemia (AML) patients, linked to modest cell-type-dependent cytotoxicity and reduced impact on DNA methylation.27 This evidence concerns the gene CD274 and acute myeloid leukemia.